These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34000917)

  • 1. Trastuzumab-emtansine induced pleural and pericardial effusions.
    Lombardi J; Lory P; Martin N; Mayeur D; Combret S; Grandvuillemin A; Boulay C; Schmitt A
    J Oncol Pharm Pract; 2021 Dec; 27(8):2041-2044. PubMed ID: 34000917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ado-trastuzumab emtansine associated spider telangiectasia.
    Gursoy P; Acar A; Acikalin T
    J Oncol Pharm Pract; 2022 Jun; 28(4):986-988. PubMed ID: 35040682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
    Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?
    Lepelley M; Allouchery M; Long J; Boucherle D; Ranchoup Y; Le Marc'Hadour F; Villier C; Sturm N
    Ann Hepatol; 2018 Oct; 17(6):1067-1071. PubMed ID: 30600283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab emtansine for HER2-positive advanced breast cancer.
    Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
    N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.
    Yamamoto H; Ando M; Aogi K; Iwata H; Tamura K; Yonemori K; Shimizu C; Hara F; Takabatake D; Hattori M; Asakawa T; Fujiwara Y
    Jpn J Clin Oncol; 2015 Jan; 45(1):12-8. PubMed ID: 25332421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.
    Barginear MF; John V; Budman DR
    Mol Med; 2013 Jan; 18(1):1473-9. PubMed ID: 23196784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine.
    Muzaffar M; Jia J; Liles D; Naveed M; Kumari A
    Am J Ther; 2016; 23(2):e572-4. PubMed ID: 25756468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
    Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity.
    Yan H; Endo Y; Shen Y; Rotstein D; Dokmanovic M; Mohan N; Mukhopadhyay P; Gao B; Pacher P; Wu WJ
    Mol Cancer Ther; 2016 Mar; 15(3):480-90. PubMed ID: 26712117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical research progress of T-DM1 in breast cancer].
    Li LX; Ma F
    Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):92-97. PubMed ID: 33472319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab emtansine: mechanisms of action and drug resistance.
    Barok M; Joensuu H; Isola J
    Breast Cancer Res; 2014 Mar; 16(2):209. PubMed ID: 24887180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients.
    Lee A; Larck C; Moore DC
    J Oncol Pharm Pract; 2022 Jan; 28(1):49-54. PubMed ID: 33356991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy.
    Dhillon S
    Drugs; 2014 Apr; 74(6):675-86. PubMed ID: 24659374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab.
    LaMorte D; Desmond D; Ellis J; Lipkowitz S
    BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
    Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
    Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis.
    Salvestrini V; Kim K; Caini S; Alkner S; Ekholm M; Skyttä T; Becherini C; Coles CE; Kaidar-Person O; Offersen B; de Azambuja E; Visani L; Cortes J; Harbeck N; Rugo HS; Isacke CM; Marangoni E; Morandi A; Lambertini M; Poortmans P; Livi L; Meattini I
    Radiother Oncol; 2023 Sep; 186():109805. PubMed ID: 37437610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
    Lu D; Girish S; Gao Y; Wang B; Yi JH; Guardino E; Samant M; Cobleigh M; Rimawi M; Conte P; Jin JY
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):399-410. PubMed ID: 24939213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.